NOVELTY – Use of fucosylated chondroitin sulfate compound is claimed for developing drugs for preventing severe forms of malaria and used with complementary therapy. USE – Used in pharmaceutical composition and for developing drugs for preventing severe forms of malaria and used with complementary therapy (claimed), particularly used for treating cerebral and gestational malaria caused by Plasmodium falciparum. ADVANTAGE – The fucosylated chondroitin sulfate compound inhibits endothelial inflammation associated with disease.
B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.)